These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 8438482

  • 21. Prolonged survival of mouse cardiac allografts after CD4 or CD8 monoclonal antibody therapy is associated with selective intragraft cytokine protein expression: interleukin (IL)-4 and IL-10 but not IL-2 or interferon-gamma.
    Hancock W, Mottram PL, Purcell LJ, Han WR, Pietersz GA, McKenzie IF.
    Transplant Proc; 1993 Oct; 25(5):2937-8. PubMed ID: 8212290
    [No Abstract] [Full Text] [Related]

  • 22. Specific acceptance of cardiac allografts after treatment with antibodies to CD80 and CD86 in mice.
    Bashuda H, Seino K, Kano M, Sato K, Azuma M, Yagita H, Okumura K.
    Transplant Proc; 1996 Apr; 28(2):1039-41. PubMed ID: 8623220
    [No Abstract] [Full Text] [Related]

  • 23. Donor microchimerism is not responsible for the maintenance of tolerance to donor alloantigens in recipients tolerant of cardiac allografts.
    Hamano K, Rawsthorne M, Bushell A, Morris PJ, Wood KJ.
    Transplant Proc; 1995 Feb; 27(1):151-2. PubMed ID: 7878951
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Interleukin-10 eliminates anti-CD3 monoclonal antibody-induced mortality and prolongs heart allograft survival in inbred mice.
    Lowry RP, Konieczny B, Alexander D, Larsen C, Pearson T, Smith S, Narula S.
    Transplant Proc; 1995 Feb; 27(1):392-4. PubMed ID: 7879034
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A combination of anergic cells' adoptive transfer and rapamycin therapy prolongs cardiac allograft survival in mice.
    Cai Y, Tang XD, Zhou PJ.
    Scand J Immunol; 2005 Mar; 61(3):266-73. PubMed ID: 15787744
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Immunosuppression by anti-CD8 (Ly-2.1) MAb conjugated to idarubicin: studies in the mouse heart graft model.
    Mottram PL, Pietersz GA, Purcell LJ, Clunie GJ, McKenzie IF.
    Transplant Proc; 1990 Oct; 22(5):2111-2. PubMed ID: 2120812
    [No Abstract] [Full Text] [Related]

  • 37. Potent CD8+ CTLs detected in anti-CD4 (OKT4A) MAb immunosuppressed cynomolgus recipients with prolonged allograft survival.
    Wee S, Kawai T, Knowles R, Colvin R, Cosimi AB.
    Transplant Proc; 1993 Feb; 25(1 Pt 1):794-5. PubMed ID: 8438484
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Donor-specific antigen transfusion-mediated skin-graft tolerance results from the peripheral deletion of donor-reactive CD8+ T cells.
    Margenthaler JA, Kataoka M, Flye MW.
    Transplantation; 2003 Jun 27; 75(12):2119-27. PubMed ID: 12829922
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.